Assoc. Prof. DENİZ CAN GÜVEN

Publication Network

Articles 145

1. The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancer

YILMAZ F., Yaşar S., Tatar O. D., Yildirim H. c., Guven D. C., TABAN H., et al.

Acta Medica , vol.56, no.3, pp.186-198, 2025 (Peer-Reviewed Journal)

2. HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy

kahraman s., Hizal M., Gumusay O., Basaran G., Seyyar M., Sahin E., et al.

Turkish Journal of Clinics and Laboratory , vol.16, no.2, pp.255-262, 2025 (Peer-Reviewed Journal)

3. Early Changes in Volumetric Body Composition Parameters Predict Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy

AKTEPE O. H., ERDEMİR A. G., Yildirim E. C., Demirciler E., ULAŞLI T., GÜVEN D. C., et al.

JOURNAL OF CLINICAL MEDICINE , no.9, 2025 (SCI-Expanded)

4. Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors

ŞAHİN T. K., AKSOY S., GÜVEN D. C.

EXPERT REVIEW OF ANTICANCER THERAPY , no.5, pp.471-484, 2025 (SCI-Expanded)

5. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)

Majidova N., YASLIKAYA Ş., Mildanoglu M. M., COŞKUN A., ERCAN UZUNDAL D., ŞAHİN T. K., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , vol.36, no.5, pp.293-301, 2025 (SCI-Expanded)

6. Fear of Cancer Recurrence and Associated Factors in Lymphoma Survivors and Their Family Caregivers: A Cross-Sectional Study

ŞAHİN T. K., Sahin E. A., Gungor H. N., GÜVEN D. C., BARIŞTA İ., AKIN S.

CANCER MEDICINE , no.7, 2025 (SCI-Expanded)

7. The association between blood sodium levels and survival in patients treated with immune checkpoint inhibitors

ŞAHİN T. K., GÜVEN D. C., Durukan M., KAVGACI G., KAYGUSUZ Y., ARIK Z., et al.

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS , no.4, pp.129-137, 2025 (SCI-Expanded)

8. Modified cachexia index and survival in metastatic breast cancer patients treated with CDK 4-6 inhibitors

BAŞ O., Tokatli M., Savkliyildiz M., Yazarkan Y., Guduk N., Kilinc C., et al.

EXPERT REVIEW OF ANTICANCER THERAPY , no.4, pp.405-409, 2025 (SCI-Expanded)

9. Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer

Sahin T. K., Rizzo A., GÜVEN D. C., AKSOY S.

CANCER TREATMENT REVIEWS , 2025 (SCI-Expanded)

10. Clinical Characteristics and Management of Patients Admitted to the Supportive Care Clinic and Predisposing Factors of Unplanned Hospital Readmission: Single-Center Experience

BAŞ O., Tokatli M., Guduk N., Erdogan D., Boyraz N. E., Cengelci C., et al.

JOURNAL OF CLINICAL MEDICINE , no.8, 2025 (SCI-Expanded)

11. Comparative Analysis of Prognostic Potential of Pretreatment Blood-Based Biomarkers in Metastatic Bladder Cancer: Modified Glasgow Prognostic Score

KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., Koc I., Tatar O. D., et al.

JOURNAL OF CLINICAL MEDICINE , no.6, 2025 (SCI-Expanded)

12. Efficacy of Immunotherapy Versus Chemotherapy in Advanced Pleural Mesothelioma: A Turkish Oncology Group (TOG) Study

Kalkan Z., Ebinç S., Arcagok M., BİLİCİ A., YILDIZ Ö., KILIÇKAP S., et al.

MEDICINA-LITHUANIA , no.4, 2025 (SCI-Expanded)

13. Serum Albumin-Creatinine Ratio and Anthracycline Cardiotoxicity in Patients with Cancer

BAŞ O., Guduk N., Tokatli M., Guven D. C., ÖZER N., ŞENER Y. Z., et al.

JOURNAL OF CLINICAL MEDICINE , no.5, 2025 (SCI-Expanded)

14. The perspectives and knowledge of patients with cancer on mpox and mpox vaccination: a cross-sectional study

ŞAHİN T. K., KAYGUSUZ Y., Icli M. C., AKSOY S., GÜVEN D. C.

CURRENT MEDICAL RESEARCH AND OPINION , no.1, pp.83-91, 2025 (SCI-Expanded)

15. The association between HALP score and survival in patients treated with immune checkpoint inhibitors

ŞAHİN T. K., GÜVEN D. C., Durukan M., BAŞ O., KAYGUSUZ Y., ARIK Z., et al.

EXPERT REVIEW OF ANTICANCER THERAPY , no.1, pp.81-89, 2025 (SCI-Expanded)

16. Monitoring Over Time of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Through an Ensemble Vision Transformers-Based Model

Comes M. C., Fanizzi A., Bove S., Boldrini L., Latorre A., GÜVEN D. C., et al.

CANCER MEDICINE , vol.13, no.24, 2024 (SCI-Expanded)

17. Activity of CDK4/6 inhibitors and parameters affecting survival in elderly patients in age-subgroups: Turkish Oncology Group (TOG) retrospective study

Kahraman S., Hizal M., Demirel B. C., GÜVEN D. C., GÜMÜŞAY Ö., OYAN ULUÇ B., et al.

BMC CANCER , vol.24, no.1, 2024 (SCI-Expanded)

18. Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer

YILMAZ F., YAŞAR S., Tatar O. D., Yildirim H. C., Guven D. C., AKYILDIZ A., et al.

BMC CANCER , vol.24, no.1, 2024 (SCI-Expanded)

19. Sex differences in adverse events among cancer patients receiving immune checkpoint inhibitors: the MOUSEION-07 systematic review and meta-analysis

Vitale E., Rizzo A., Maistrello L., GÜVEN D. C., Massafra R., Mollica V., et al.

SCIENTIFIC REPORTS , vol.14, no.1, 2024 (SCI-Expanded)

20. Post-operative serum CEA predicts prognosis in HR-positive/HER2-negative early breast cancer

KAVGACI G., ŞAHİN T. K., Muderrisoglu T., Ileri S., GÜVEN D. C., AKSOY S.

EXPERT REVIEW OF ANTICANCER THERAPY , no.12, pp.1319-1326, 2024 (SCI-Expanded) Sustainable Development

21. Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancer

AKYILDIZ A., Ismayilov R., Abdurrahimli N., Ormanci A., GÜVEN D. C., TUNCEL M., et al.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY , no.2, pp.100-105, 2024 (SCI-Expanded)

22. Prognostic impact of myosteatosis on survival with immune checkpoint inhibitors: A systematic review and meta-analysis

Sahin T. K., Guven D. C.

CLINICAL NUTRITION ESPEN , vol.63, pp.829-836, 2024 (ESCI)

23. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Guzel H. G., et al.

JOURNAL OF CHEMOTHERAPY , 2024 (SCI-Expanded)

24. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)

AKYILDIZ A., GÜVEN D. C., KÖKSAL B., KARAOĞLAN B. B., Kivrak D., Ismayilov R., et al.

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY , vol.281, no.9, pp.4991-4999, 2024 (SCI-Expanded)

25. Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab

YILDIRIM H. Ç., Anik H., ATEŞ ÖZDEMİR D., Ismayilov R., AKYILDIZ A., ÇAYIRÖZ K., et al.

BIOMOLECULES AND BIOMEDICINE , vol.24, no.4, pp.998-1003, 2024 (SCI-Expanded)

26. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer

YILDIRIM H. Ç., Buyukkor M., KAVGACI G., ŞAHİN ÇELİK B., BİR YÜCEL K., DURSUN B., et al.

MEDICINE , vol.103, no.30, 2024 (SCI-Expanded)

27. Impact of opioid analgesics on survival in cancer patients receiving immune checkpoint inhibitors

KAVGACI G., GÜVEN D. C., KAYGUSUZ Y., KARACA E., DİZDAR Ö., Kilickap S., et al.

SUPPORTIVE CARE IN CANCER , vol.32, no.7, 2024 (SCI-Expanded) Sustainable Development

28. Prognostic Significance of Pan-Immune-Inflammation Value in Patients with HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab Emtansine

ŞAHİN T. K., AKYILDIZ A., DOĞAN O. T., KAVGACI G., GÜVEN D. C., AKSOY S.

PHARMACEUTICALS , vol.17, no.7, 2024 (SCI-Expanded)

29. The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer: A Systematic Review

GÜVEN D. C., KAVGACI G., ERUL E., Syed M. P., Magge T., Saeed A., et al.

ONCOLOGIST , vol.29, 2024 (SCI-Expanded)

30. Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis

Sahin T. K., Rizzo A., AKSOY S., Guven D. C.

CANCERS , vol.16, no.10, 2024 (SCI-Expanded)

31. Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

Schipilliti F. M., Drittone D., Mazzuca F., La Forgia D., GÜVEN D. C., Rizzo A.

Heliyon , vol.10, no.7, 2024 (SCI-Expanded)

32. The association between HER2-low status and survival in patients with metastatic breast cancer treated with Cyclin-dependent kinases 4 and 6 inhibitors: a systematic review and meta-analysis

Guven D. C., Sahin T. K.

Breast Cancer Research and Treatment , vol.204, no.3, pp.443-452, 2024 (SCI-Expanded)

33. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

Yıldırım H. Ç., KUTLU Y., Mutlu E., Aykan M. B., Korkmaz M., Yalçın S., et al.

International Journal of Clinical Oncology , vol.29, no.3, pp.258-265, 2024 (SCI-Expanded)

34. Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer

Karacin C., Sunar V., Urakci Z., YILMAZ A., Ayhan M., Ersoy M., et al.

Future oncology (London, England) , vol.20, no.4, pp.207-214, 2024 (SCI-Expanded)

35. Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review

GÜVEN D. C., Thong M. S., Arndt V.

Journal of Cancer Survivorship , 2024 (SCI-Expanded)

36. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing

KÖSTEK O., Demirel A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündogdu A., et al.

Journal of Chemotherapy , 2024 (SCI-Expanded)

37. Editorial: Advances in the treatment of hormonal receptor positive (HR plus ) breast cancer

Ben Kridis W., Wang Z., GÜVEN D. C., Dharmarajan A.

FRONTIERS IN ONCOLOGY , vol.14, 2024 (SCI-Expanded)

38. The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study

KUŞ F., GÜVEN D. C., YILDIRIM H. Ç., Akagunduz B., Karakaya S., SÜTCÜOĞLU O., et al.

INTEGRATIVE CANCER THERAPIES , vol.23, 2024 (SCI-Expanded)

39. Unveiling cancer risk in ANCA-associated vasculitis: result from the Turkish Vasculitis Study Group (TRVaS)

BİLGİN E., Demirci Yıldırım T., Özdemir Ulusoy B., Öğüt T. S., Karabacak M., Sadioğlu Çağdaş Ö., et al.

Internal and Emergency Medicine , 2024 (SCI-Expanded)

40. Immunotherapy in the First-Line Treatment of Advanced Nasopharyngeal Carcinoma: A Systematic Review and Meta-Analysis

GÜVEN D. C., Stephen B., ŞAHİN T. K., ÇAKIR İ. Y., AKSOY S.

Laryngoscope , vol.134, no.1, pp.7-17, 2024 (SCI-Expanded)

41. Sacituzumab govitecan vs. chemotherapy for metastatic breast cancer: a meta-analysis on safety outcomes

Rizzo A., Rinaldi L., Massafra R., Cusmai A., GÜVEN D. C., Forgia D. L., et al.

FUTURE ONCOLOGY , vol.20, no.20, pp.1427-1434, 2024 (SCI-Expanded) Sustainable Development

42. Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy

Sahin T. K., ÖZBAY Y., ALTUNBULAK A. Y., ALTUNBULAK H. İ., ONUR M. R., Ceylan F., et al.

International Journal of Clinical Oncology , 2024 (SCI-Expanded)

43. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study

Karadurmus N., Kaplan M. A., Sendur M. A. N., ÜRÜN Y., Demirci U., Karaca S. B., et al.

CURRENT MEDICAL RESEARCH AND OPINION , vol.40, pp.1171-1178, 2024 (SCI-Expanded) Sustainable Development

44. Immunobiology of biliary tract cancer and recent clinical findings in approved and upcoming immune checkpoint inhibitors

Laface C., Fina E., Ricci A. D., GÜVEN D. C., Ambrogio F., De Summa S., et al.

EXPERT OPINION ON BIOLOGICAL THERAPY , vol.24, pp.1363-1374, 2024 (SCI-Expanded)

45. Sirolimus experience in adult patients with vascular malformations

AKYILDIZ A., Ismayilov R., GÜVEN D. C., YILDIRIM H. Ç., Tatar O. D., KUŞ F., et al.

Vascular , 2024 (SCI-Expanded)

46. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study

Guven D. C., Aykan M. B., MUĞLU H., BAYRAM E., Helvaci K., DURSUN B., et al.

Cancer Medicine , vol.13, no.1, 2024 (SCI-Expanded)

47. Comparison between vision transformers and convolutional neural networks to predict non-small lung cancer recurrence

Fanizzi A., Fadda F., Comes M. C., Bove S., Catino A., Di Benedetto E., et al.

Scientific Reports , vol.13, no.1, 2023 (SCI-Expanded)

48. A meta-analysis of the association between adjuvant chemoradiotherapy and disease-free survival in gastric cancer according to the histology

YILDIRIM H. Ç., GÜVEN D. C., AKYILDIZ A., YALÇIN Ş., DİZDAR Ö.

Irish Journal of Medical Science , vol.192, no.6, pp.2631-2634, 2023 (SCI-Expanded) Sustainable Development

49. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

AKYILDIZ A., GÜVEN D. C., Ozluk A. A., Ismayilov R., Mutlu E., Unal O. U., et al.

Medicine , vol.102, no.45, 2023 (SCI-Expanded)

50. A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer

YILDIRIM H. Ç., Ismayilov R., AKYILDIZ A., GÜVEN D. C., Abdurrahimli N., DİZDAR Ö., et al.

Anti-cancer drugs , vol.34, no.10, pp.1190-1192, 2023 (SCI-Expanded)

51. Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab

YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., et al.

Journal of Immunotherapy and Precision Oncology , vol.6, no.4, pp.170-176, 2023 (Scopus)

52. Seven-Year Single-Center Experience of the Efficacy and Safety of Ferric Carboxymaltose in Cancer Patients with Iron-Deficiency Anemia

AKTAŞ B. Y., ATA E. B., ÇEŞMECİ E., ÇAKIR İ. Y., Coşkunpınar M., TAHILLIOĞLU Y., et al.

Current Oncology , vol.30, no.11, pp.9689-9700, 2023 (SCI-Expanded)

53. Looking at FOxTROT Through the Lens of IDEA

GÜVEN D. C.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology , vol.41, no.30, pp.4821-4822, 2023 (SCI-Expanded)

54. Comparison of Adjuvant Modified FOLFIRINOX with Other Adjuvant Chemotherapies in Resected Pancreatic Adenocarcinoma: Real-life Data

EROL C., HAFIZOĞLU E., aykan m. b., GÜVEN D. C., Dursun B., Hizal M., et al.

ACTA ONCOLOGICA TURCICA , vol.56, no.2, pp.170-179, 2023 (Peer-Reviewed Journal)

55. Comparison of PD-L1 and VISTA expression status in primary and recurrent/refractory tissue after (chemo)radiotherapy in head and neck cancer

Şener G. Y., SÜTCÜOĞLU O., ÖĞÜT B., GÜVEN D. C., KAVUNCUOĞLU A., ÖZDEMİR N., et al.

Strahlentherapie und Onkologie , vol.199, no.8, pp.761-772, 2023 (SCI-Expanded)

56. Role of sarcopenia on survival and treatment-related toxicity in head and neck cancer: a narrative review of current evidence and future perspectives

ERUL E., GÜVEN D. C., ONUR M. R., YAZICI G., AKSOY S.

European Archives of Oto-Rhino-Laryngology , vol.280, no.8, pp.3541-3556, 2023 (SCI-Expanded)

57. The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., et al.

Anti-Cancer Drugs , vol.34, no.6, pp.783-790, 2023 (SCI-Expanded)

58. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study

GÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.149, no.7, pp.3599-3606, 2023 (SCI-Expanded)

59. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)

Hizal M., Bilgin B., Paksoy N., Atci M. M., KAHRAMAN S., Kilickap S., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.149, no.8, pp.4141-4148, 2023 (SCI-Expanded)

60. SMART syndrome: a case report

Bozkurt S., Toprak B., YILDIRIM H. Ç., PARLAK SAĞOL Ş., GÜVEN D. C., KERTMEN N., et al.

ACTA NEUROLOGICA BELGICA , vol.123, no.3, pp.1137-1140, 2023 (SCI-Expanded)

61. Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort

AKYILDIZ A., GÜVEN D. C., YILDIRIM H. Ç., Ismayilov R., YILMAZ F., Tatar O. D., et al.

Medicine (United States) , vol.102, no.18, 2023 (SCI-Expanded)

62. The association between pan-immune-inflammation value and survival in head and neck squamous cell carcinoma

GÜVEN D. C., ERUL E., YILMAZ F., YAŞAR S., YILDIRIM H. Ç., ERCAN F., et al.

European Archives of Oto-Rhino-Laryngology , vol.280, no.5, pp.2471-2478, 2023 (SCI-Expanded)

63. Learning From Failure: Negative Trials in Oncology

Nardo M., GÜVEN D. C., Yikilmaz A. S., Singh S., Ahmed J.

Journal of Immunotherapy and Precision Oncology , vol.6, no.2, pp.59-60, 2023 (Scopus)

64. Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Kahraman S., ERUL E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., et al.

Future oncology (London, England) , vol.19, no.10, pp.727-736, 2023 (SCI-Expanded)

65. Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer

Ceylan F., Guven D. C., Taban H., Aktepe O., ŞAHİN T. K., Kilickap S., et al.

Clinics and Research in Hepatology and Gastroenterology , vol.47, no.3, 2023 (SCI-Expanded) Sustainable Development

66. Tailoring adjuvant chemotherapy by circulating tumor DNA (ctDNA) in older patients with stage II-III colon cancer

Akagunduz B., Guven D. C., Ozer M., Okten I. N., Atag E., Unek İ. T., et al.

Journal of Geriatric Oncology , vol.14, no.2, 2023 (SCI-Expanded) Sustainable Development

67. Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy

GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., et al.

INTERNATIONAL JOURNAL OF CANCER , vol.152, pp.679-685, 2023 (SCI-Expanded)

68. Emerging treatment strategies in hepatobiliary cancer

GÜVEN D. C., YILDIRIM H. Ç., Chalabiyev E., KUŞ F., YILMAZ F., YAŞAR S., et al.

Expert Review of Anticancer Therapy , vol.23, no.3, pp.243-256, 2023 (SCI-Expanded) Sustainable Development

69. Unresectable Hepatocellular Carcinoma and Prognostic Factors of Sorafenib Treatment: A Real-Life Experience

Erol C., Bardakçi M., Hizal M., Kahraman S., Yekedüz E., GÜVEN D. C., et al.

Journal of Oncological Science , vol.9, no.2, pp.72-78, 2023 (Scopus)

70. Prognostic Value of Androgen Receptor Expression in Premenopausal Women with Estrogen Receptor-Positive Breast Cancer

YILDIRIM H. Ç., ÜNER M., Yildiran Özmen T., Chalabiyev E., GÜVEN D. C., KUŞ F., et al.

Journal of Oncological Science , vol.9, no.1, pp.33-37, 2023 (Scopus)

71. Optimal adjuvant treatment strategies for TNBC patients with residual disease after neoadjuvant treatment

Guven D. C., YILDIRIM H. Ç., KUŞ F., Erul E., KERTMEN N., DİZDAR Ö., et al.

Expert Review of Anticancer Therapy , vol.23, no.10, pp.1049-1059, 2023 (SCI-Expanded)

72. The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

GÜVEN D. C., ŞAHİN T. K., ERUL E., Rizzo A., Ricci A. D., AKSOY S., et al.

Frontiers in Molecular Biosciences , vol.9, 2022 (SCI-Expanded)

73. Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group

Gurbuz M., Kutlu Y., AKKUŞ E., KÖKSOY E. B., Kose N., Oven B. B., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.12, pp.3547-3555, 2022 (SCI-Expanded) Sustainable Development

74. Bilateral primary breast lymphoma in a pregnant woman: a case report and literature review

YILDIRIM H. Ç., AKYILDIZ A., Ismayilov R., Demirok N., BENLİ B. S., Guven D. C., et al.

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY , vol.15, no.4, pp.307-310, 2022 (ESCI)

75. Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study

YILDIRIM H. Ç., MUTLU E., Chalabiyev E., Ozen M., KESKİNKILIÇ M., ÖN S., et al.

BREAST , vol.66, pp.85-88, 2022 (SCI-Expanded)

76. Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards

GÜVEN D. C., EROĞLU İ., Ismayilov R., ULUSOYDAN E., AKTEPE O. H., TELLİ DİZMAN G., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.8, pp.1807-1811, 2022 (SCI-Expanded) Sustainable Development

77. SARS-CoV-2 Vaccine Efficacy in Patients with Hematologic Malignancies: Practical Points for Further Research

GÜVEN D. C., Sahin T. K., AKIN S., Uckun F. M.

ONCOLOGIST , vol.27, no.11, 2022 (SCI-Expanded) Sustainable Development

78. Infectious complications of cyclin-dependent kinases 4 and 6 inhibitors in patients with hormone-receptor-positive metastatic breast cancer: a systematic review and meta-analysis

BAŞ O., Erul E., GÜVEN D. C., AKSOY S.

SUPPORTIVE CARE IN CANCER , vol.30, no.11, pp.9071-9078, 2022 (SCI-Expanded)

79. Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine

Carloni R., Rizzo A., Ricci A. D., Di Federico A., De Luca R., GÜVEN D. C., et al.

TRANSLATIONAL ONCOLOGY , vol.25, 2022 (SCI-Expanded)

80. The Use of Phytochemicals to Improve the Efficacy of Immune Checkpoint Inhibitors: Opportunities and Challenges

GÜVEN D. C., ŞAHİN T. K., Rizzo A., Ricci A. D., AKSOY S., ŞAHİN K.

APPLIED SCIENCES-BASEL , vol.12, no.20, 2022 (SCI-Expanded)

81. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.

JOURNAL OF CLINICAL MEDICINE , vol.11, no.17, 2022 (SCI-Expanded)

82. Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis

Rizzo A., Carloni R., Ricci A. D., Di Federico A., GÜVEN D. C., YALÇIN Ş., et al.

JOURNAL OF PERSONALIZED MEDICINE , vol.12, no.8, 2022 (SCI-Expanded)

83. The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy

GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., et al.

JOURNAL OF CLINICAL MEDICINE , vol.11, no.15, 2022 (SCI-Expanded)

84. Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report

TABAN H., GÜVEN D. C., Kilickap S.

CUREUS JOURNAL OF MEDICAL SCIENCE , vol.14, no.8, 2022 (ESCI)

85. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Hizal M., Bilgin B., Paksoy N., Acikgoz O., Sezer A., Gurbuz M., et al.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.148, no.6, pp.1501-1508, 2022 (SCI-Expanded)

86. The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy

GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.28, no.4, pp.785-793, 2022 (SCI-Expanded) Sustainable Development

87. The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis

GÜVEN D. C., ŞAHİN T. K., Erul E., KILIÇKAP S., Gambichler T., AKSOY S.

CANCERS , vol.14, no.11, 2022 (SCI-Expanded)

88. Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.

Guven D. C., Sayegh N., Tripathi N., Erman M., Agarwal N., Swami U.

JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16, 2022 (SCI-Expanded)

89. Trastuzumab +/- Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group

Gurbuz M., Akkus E., Sakin A., Urvay S., Demiray A. G., Sahin S., et al.

JOURNAL OF GASTROINTESTINAL CANCER , vol.53, no.2, pp.282-288, 2022 (ESCI) Sustainable Development

90. The efficacy of immune checkpoint inhibitors in rare tumors: A systematic review of published clinical trials

GÜVEN D. C., Stephen B., ŞAHİN T. K., ÇAKIR İ. Y., Erul E., AKSOY S.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY , vol.174, 2022 (SCI-Expanded)

91. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination

GÜVEN D. C., Sahin T. K., AKIN S., Uckun F. M.

ONCOLOGIST , vol.27, 2022 (SCI-Expanded)

92. HER2-low breast cancer could be associated with an increased risk of brain metastasis

GÜVEN D. C., KAYA M. B., Fedai B., ÖZDEN M., YILDIRIM H. Ç., KÖSEMEHMETOĞLU K., et al.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY , vol.27, no.2, pp.332-339, 2022 (SCI-Expanded) Sustainable Development

93. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy

YILDIRIM H. Ç., Güven D. C., Chalabiyev E., Taban H., YILMAZ F., YAŞAR S., et al.

Journal of Oncological Science , vol.8, no.3, pp.143-147, 2022 (Scopus)

94. The use of fulvestrant before chemotherapy improves survival in hormone-positive breast cancer: a real-life study

GÜVEN D. C., YILDIRIM H. Ç., ERUL E., ŞAHİN T. K., ÇAKIR İ. Y., AKTEPE O. H., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , vol.52, no.5, pp.1551-1558, 2022 (SCI-Expanded)

95. Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma

Gurler F., GÜVEN D. C., Aydemir E., SÜTCÜOĞLU O., Inci B. K., ARIK Z., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , vol.52, no.5, pp.1559-1568, 2022 (SCI-Expanded)

96. Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment

GÜRLER F., Ilhan A., GÜVEN D. C., TURHAN O., KURT İNCİ B., SÜTCÜOĞLU O., et al.

ANTI-CANCER DRUGS , vol.33, no.1, 2022 (SCI-Expanded)

97. Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., et al.

FUTURE ONCOLOGY , vol.18, pp.323-331, 2022 (SCI-Expanded) Sustainable Development

98. Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., et al.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , vol.6, no.1, pp.59-63, 2022 (ESCI) Sustainable Development

99. Correlation Between THSD7A Expression and Tumor Characteristics of Azoxymethane-Induced Colon Cancer Model in Rats

AKTEPE O. H., ŞAHİN T. K., GÜNER G., GÜVEN D. C., YETER H. H., KURTULAN O., et al.

TURKISH JOURNAL OF GASTROENTEROLOGY , vol.32, no.12, pp.1049-1056, 2021 (SCI-Expanded) Sustainable Development

100. Assessment of abuse and related factors in older patients with cancer

Akagunduz B., Altin Z., Atci M. M., Ozer M., GÜVEN D. C., Cil I., et al.

SUPPORTIVE CARE IN CANCER , vol.29, no.12, pp.7957-7964, 2021 (SCI-Expanded) Sustainable Development

101. The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study

GÜVEN D. C., Acar R., Yekeduz E., Bilgetekin I., Baytemur N. K., EROL C., et al.

CURRENT PROBLEMS IN CANCER , vol.45, no.6, 2021 (SCI-Expanded)

102. A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., AKTEPE O. H., DİZDAR Ö., YALÇIN Ş.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY , vol.168, 2021 (SCI-Expanded) Sustainable Development

103. Thirty-day mortality rates after immunotherapy initiation

SÜTCÜOĞLU O., Ilhan A., Tacar S. Y., GÜVEN D. C., Ucar G., Karadurmus N., et al.

IMMUNOTHERAPY , vol.13, pp.1419-1426, 2021 (SCI-Expanded)

104. Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review

GÜVEN D. C., ŞAHİN T. K., KILIÇKAP S., Uckun F. M.

FRONTIERS IN ONCOLOGY , vol.11, 2021 (SCI-Expanded)

105. The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy

AKTEPE O. H., GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇELİKTEN B., Yeter H. H., et al.

NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL , vol.73, no.10, pp.1957-1963, 2021 (SCI-Expanded)

106. The association of BMI and sarcopenia with survival in patients with glioblastoma multiforme

GÜVEN D. C., AKSUN M. S., ÇAKIR İ. Y., KILIÇKAP S., KERTMEN N.

FUTURE ONCOLOGY , vol.17, pp.4405-4413, 2021 (SCI-Expanded) Sustainable Development

107. Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality

GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇEŞMECİ E., Incesu F. G. G., TAHILLIOĞLU Y., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded)

108. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., et al.

SUPPORTIVE CARE IN CANCER , vol.29, no.9, pp.5417-5423, 2021 (SCI-Expanded) Sustainable Development

109. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors

GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., et al.

BIOMARKERS IN MEDICINE , vol.15, no.13, pp.1123-1130, 2021 (SCI-Expanded) Sustainable Development

110. Sarcopenia and anthracycline cardiotoxicity in patients with cancer

BAŞ O., ERDEMİR A. G., ONUR M. R., ÖZER N., ŞENER Y. Z., AKSU S., et al.

BMJ SUPPORTIVE & PALLIATIVE CARE , 2021 (SCI-Expanded) Sustainable Development

111. Neoadjuvant capecitabine in rectal cancer chemoradiotherapy: too early to ring the alarms

GÜVEN D. C., YALÇIN Ş.

INTERNAL MEDICINE JOURNAL , vol.51, no.8, pp.1365-1366, 2021 (SCI-Expanded) Sustainable Development

112. Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report

GÜVEN D. C., KILIÇKAP S., YILDIRIM H. Ç., Ceylan F., BAŞ O., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.27, no.5, pp.1281-1283, 2021 (SCI-Expanded)

113. Reassurance of patients with cancer on cancer care continuum: a vital strategy to prevent anxiety of COVID-19 collateral damage

GÜVEN D. C.

SUPPORTIVE CARE IN CANCER , vol.29, pp.3423-3424, 2021 (SCI-Expanded)

114. Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature Review

Yigit E., GÜVEN D. C., AKSOY S., YAZICI G.

CUREUS , vol.13, no.6, 2021 (ESCI)

115. A novel agnostic tumor: NTRKoma

Ayasun R., GÜVEN D. C., Gullu İ. H.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.27, no.4, pp.802-803, 2021 (SCI-Expanded)

116. Artificial intelligence method to predict overall survival of hepatocellular carcinoma

ŞİMŞEK C., GÜVEN D. C., Sahin T. K., TEKİN İ. E., Sahan O., BALABAN H. Y., et al.

Hepatology Forum , vol.2, no.2, pp.64-68, 2021 (Scopus)

117. THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY

GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION , vol.36, 2021 (SCI-Expanded)

118. The relation between inflammation-based parameters and survival in metastatic pancreatic cancer

Turker S., Cilbir E., GÜVEN D. C., Karacin C., YALÇIN Ş.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , vol.17, no.2, pp.510-515, 2021 (SCI-Expanded) Sustainable Development

119. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors

GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., et al.

SUPPORTIVE CARE IN CANCER , vol.29, no.4, pp.2029-2035, 2021 (SCI-Expanded) Sustainable Development

120. Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma

AKTEPE O. H., GÜNER G., GÜVEN D. C., TABAN H., YILDIRIM H. Ç., ŞAHİN T. K., et al.

TURKISH JOURNAL OF UROLOGY , vol.47, no.2, pp.113-119, 2021 (ESCI)

121. Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., Olgun P., et al.

CANCER RESEARCH , vol.81, no.4, 2021 (SCI-Expanded) Sustainable Development

122. Thyroid gland metastasis mimicking thyroid carcinoma in a lung cancer patient and dramatic response to crizotinib: A case report

Erul E., GÜVEN D. C., ŞAHİN T. K., Gullu İ. H.

TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX , vol.69, no.1, pp.98-101, 2021 (ESCI)

123. The use of CDK 4/6 inhibitors in the adjuvant treatment of breast cancer: Timing matters

GÜVEN D. C., ŞAHİN T. K., AKSOY S.

BREAST JOURNAL , vol.26, no.12, pp.2435-2436, 2020 (SCI-Expanded) Sustainable Development

124. Cancer incidence in Behcet's disease

GÜVEN D. C., BÖLEK E. Ç., ALTINTOP S. E., ÇELİKTEN B., AKTAŞ B. Y., KİRAZ S., et al.

IRISH JOURNAL OF MEDICAL SCIENCE , vol.189, no.4, pp.1209-1214, 2020 (SCI-Expanded) Sustainable Development

125. Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)

Alkan A., Yasar A., Guc Z. G., Gurbuz M., BAŞOĞLU TÜYLÜ T., SEZGİN GÖKSU S., et al.

EUROPEAN JOURNAL OF CANCER CARE , vol.29, no.6, 2020 (SCI-Expanded) Sustainable Development

126. Effects of adenosine triphosphate on vandetanib induced skin damage in rats

Akagunduz B., ÖZÇİÇEK F., Kara A. V., GÜVEN D. C., YAZICI G. N., Coban A., et al.

CUTANEOUS AND OCULAR TOXICOLOGY , vol.39, no.4, pp.323-327, 2020 (SCI-Expanded)

127. Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design

GÜVEN D. C., GÜNER G., AKTAŞ B. Y., AKTEPE O. H., TABAN H., ARIK Z.

CLINICAL COLORECTAL CANCER , vol.19, no.3, 2020 (SCI-Expanded) Sustainable Development

128. All Positives May Not Be the Same in Pancreatic Cancer Lessons Learned From the Past

Ceylan F., GÜVEN D. C., ŞAHİN T. K., ÖZBEK D. A., DİZDAR Ö.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS , vol.43, no.9, pp.676, 2020 (SCI-Expanded) Sustainable Development

129. Perspectives, Knowledge, and Fears of Cancer Patients About COVID-19

GÜVEN D. C., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., AKSOY S., KILIÇKAP S.

FRONTIERS IN ONCOLOGY , vol.10, 2020 (SCI-Expanded)

130. Cancer incidence in Behcet's Disease.

Guven D. C., Bolek E. C., Altintop S. E., Celikten B., Aktas B. Y., Kiraz S., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15, 2020 (SCI-Expanded)

131. Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications

GÜVEN D. C., AKTAŞ B. Y., ŞİMŞEK C., AKSOY S.

FUTURE ONCOLOGY , vol.16, no.9, pp.497-506, 2020 (SCI-Expanded)

132. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient

KILIÇKAP S., GÜVEN D. C., AKTEPE O. H., AKTAŞ B. Y., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.2, pp.496-499, 2020 (SCI-Expanded)

133. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer

GÜVEN D. C., KILIÇKAP S., GÜNER G., TABAN H., DİZDAR Ö.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE , vol.26, no.1, pp.256-258, 2020 (SCI-Expanded) Sustainable Development

134. Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study

Sunar V., Korkmaz V., AKIN S., GÜVEN D. C., ARIK Z., Ates O., et al.

JOURNAL OF BUON , vol.24, no.6, pp.2327-2332, 2019 (SCI-Expanded)

135. Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy

AKTAŞ B. Y., Guner G., Guven D. C., Arslan C., DİZDAR Ö.

EXPERT REVIEW OF ANTICANCER THERAPY , vol.19, no.7, pp.589-601, 2019 (SCI-Expanded) Sustainable Development

136. Analysis of Fusobacterium nucleatum and Streptococcus gallolyticus in saliva of colorectal cancer patients

Guven D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., et al.

BIOMARKERS IN MEDICINE , vol.13, no.9, pp.725-735, 2019 (SCI-Expanded) Sustainable Development

137. Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia

BİLGİN E., DİZDAR Ö., Guven D. C., Ceylan S., AYBI Ö., FIRLATAN B., et al.

Rheumatology International , vol.39, no.6, pp.1045-1051, 2019 (SCI-Expanded) Sustainable Development

138. Evaluation of cancer risk in patients with periodontal diseases

Guven D. C., DİZDAR Ö., AKMAN A. C., Berker E., Yekeduz E., Ceylan F., et al.

TURKISH JOURNAL OF MEDICAL SCIENCES , vol.49, no.3, pp.826-831, 2019 (SCI-Expanded)

139. A rare cause of proximal muscle weakness: immune necrotising myopathy

GÜVEN D. C., ERDEN A., KILIÇ L., ERDEM ÖZDAMAR S., KARADAĞ Ö.

SCOTTISH MEDICAL JOURNAL , vol.63, no.3, pp.82-86, 2018 (SCI-Expanded)

140. Fusobacterium and colorectal carcinogenesis

Guven D. C., DİZDAR Ö.

CARCINOGENESIS , vol.39, no.1, pp.84, 2018 (SCI-Expanded)

141. Increased cancer risk in patients with periodontitis

DİZDAR Ö., HAYRAN M., Guven D. C., YILMAZ T. B., TAHERI S., AKMAN A. C., et al.

CURRENT MEDICAL RESEARCH AND OPINION , vol.33, no.12, pp.2195-2200, 2017 (SCI-Expanded) Sustainable Development

142. An Unusual Case of Tuberculosis Lenfadenitis Mimicking Tularemia

Başpınar B., HELVACI Ö., GÜVEN D. C., İNKAYA A. Ç.

Turkiye Klinikleri Journal of Internal Medicine , vol.1, no.2, pp.111-113, 2016 (Peer-Reviewed Journal)

143. Prognostic Factors In Breast Cancer Patients With Hepatic Metastases: Impact Of Molecular Subtype And Local Hepatic Treatment

ATEŞ Ö., GÜVEN D. C., BABACAN T., Sunar V., Sarici F., AKSOY S., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.26, no.4, pp.206-214, 2016 (SCI-Expanded)

144. Fatigue May be Independently Active at a Certain Part of Spondyloarthritis Patients: Hur-BIO Real Life Results

KALYONCU U., Erden A., KILIÇ L., Seyhoglu E., Guven D. C., AKTAŞ B. Y., et al.

ARTHRITIS & RHEUMATOLOGY , vol.67, 2015 (SCI-Expanded)

145. Acute erythroid leukemia in a patient with chronic lymphocytic leukemia

GÜVEN D. C., BABACAN T., Sarici F., AKIN S., Altundag K., Turker A.

JOURNAL OF BUON , vol.19, no.4, pp.1127, 2014 (SCI-Expanded)

Papers Presented at Peer-Reviewed Scientific Conferences 10

1. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).

Akyildiz A., Guven D. C., Koksal B., Karaoglan B. B., Salim D. K., Sutcuoglu O., et al.

Special Clinical Science Symposia, ELECTR NETWORK, 29 May 2024, (Summary Text)

2. outcomes of patients with resected pancreatic ductal adenocarcinoma

ceylan f., GÜVEN D. C., çakır y., Hamaloglu E., Karakoc D., TÜRKER F. A., et al.

9th international gastrointestinal cancer conference, 6 - 08 December 2019, (Full Text)

3. MAY CANCER RISK BE DECREASED IN A LARGE COHORT OF CHILD AND ADULT FAMILIAL MEDITERRANEAN FEVER PATIENTS?

BİLGİN E., GÜVEN D. C., Ceylan S., AYBI ÖZDEMİR Ö., KARDAŞ R. C., FIRLATAN B., et al.

Annual European Congress of Rheumatology (EULAR), Madrid, Spain, 12 - 15 June 2019, vol.78, pp.993, (Summary Text)

4. Clinical features and prognosis of patients with liposarcoma: Single-center experience.

Demir M., Guven D. C., Aktas B. Y., Guner G., Aktepe O. H., Taban H., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37, (Summary Text)

5. Kolorektal Kanserde 16S rDNA Sekanslama ile Oral Mikrobiyom Analizi

GÜVEN D. C., ERGÜNAY K., BRİNKMANN A., ALP A., AKDOĞAN KITTANA F. N., AKYÖN YILMAZ Y., et al.

2. Ulusal immünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018, (Full Text) Sustainable Development

6. Metastatic Choroidal Melanoma: Single Center Experience

AKTAŞ B. Y., GÜNER G., DEMİR M., GÜVEN D. C., AKTEPE O. H., BÖLEK E. Ç., et al.

2. Ulusal İmmunoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018, pp.1-48, (Full Text)

7. Analysis of Fusobacterium nucleatum, Streptococcus gallolyticus and Porphyromonas gingivalis in saliva in colorektal patients and healty controls. Abst ID:”e15117”

GÜVEN D. C., DİZDAR Ö., ALP A., Akdoğan Kittana F. N., KARAKOÇ D., Hamaloğlu E., et al.

2018 ASCO, Chicago, United States Of America, 1 - 05 June 2018, (Summary Text)

8. Evaluation of cancer risk in patients with periodontal diseases.

GÜVEN D. C., DİZDAR Ö., AKMAN A. C., BERKER A. E., YEKEDÜZ E., CEYLAN F., et al.

2018 ASCO Annual Meeting, Chicago, United States Of America, 1 - 05 June 2018, vol.36, pp.13571, (Summary Text)

9. Kolorektal Kanserli Hastalarda Ve Sağlıklı Kontrollerde Tükürükte Fusobacterium Nucleatum, Streptococcus Gallolyticus Ve Porphyromonas Gingivalis Analizi

GÜVEN D. C., DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N., KARAKOÇ D., HAMALOĞLU E., et al.

7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018, (Summary Text) Sustainable Development

10. SEVERE PERIODONTITIS IS ASSOCIATED WITH INCREASED CANCER RISK

DİZDAR Ö., HAYRAN K. M., GÜVEN D. C., Yılmaz T. B., Taheri S., AKMAN A. C., et al.

GAP 2017 Conference, Texas, United States Of America, 9 - 11 May 2017, (Summary Text) Sustainable Development

Books 1

1. PATOFİZYOLOJİNİN TEMELLERİ

DURUSU TANRIÖVER M., SARI A., EŞME M., KOÇ YILDIRIM S., YILDIRIM M. Ş., BÖLEK E. Ç., et al.

PALME YAYINCILIK, 2017

Metrics

Publication

156

Publication (WoS)

141

Publication (Scopus)

116

Citation (WoS)

109

H-Index (WoS)

Citation (Scopus)

221

H-Index (Scopus)

Open Access

UN Sustainable Development Goals

Publications & Works